Literature DB >> 12962299

[D-Val22]big ET-1[16-38] inhibits endothelin-converting enzyme activity: a promising concept in the prevention of cerebral vasospasm.

Michael Zimmermann1, Carla Sabine Jung, Hartmut Vatter, Andreas Raabe, Volker Seifert.   

Abstract

The aim of this study was to investigate whether the blocking of endothelin-converting enzyme (ECE) activity offers a new approach to inhibiting the development of cerebral vasospasm after subarachnoid hemorrhage (SAH) by preventing transformation of big endothelin-1 (big ET-1) to vasoactive endothelin-1 (ET-1). The effect of potential ECE inhibitors was determined in vitro by measurement of isometric contractions, induced by big ET-1, in isolated rat basilar arteries. Intact and de-endothelialized endothelium (E+ and E-, respectively) segments were examined after preincubation with the putative ECE inhibitors: phosphoramidon (10(-4) M), and [22D-Val]big ET-1 [16-38] (10(-5) M and 10(-6) M). Additionally, the effect of [D-Val22]big ET-1 [16-38] was investigated in rabbits after intracisternal application in order to inhibit the contraction of the basilar artery induced by (2x10(-6) M) big ET-1. Application of 10(-4)-M phosphoramidon resulted in a statistically significant decrease in big ET-1-induced contraction in E+ and E- segments; 10(-5)-M and 10(-6)-M [22D-Val]big ET-1 [16-38] in E- segments produced no statistically significant effect. The application of 10(-6)-M [22D-Val]big ET-1 [16-38] in E+ segments caused increased contractions, as shown by the shift to the left of the concentration-effect curve (CEC). In the rabbit group pretreated with [D-Val22]big ET-1 [16-38] (2x10(-5) M) (n=8), the angiographically measured diameter of the basilar artery increased from 0.63+/-0.12 mm to 0.66+/-0.12 mm. In the control group (n=8), this diameter decreased from 0.71+/-0.13 mm to 0.57+/-0.15 mm. This corresponded to an increase in vessel diameter of 5.24+/-9.89% in the treatment group and a decrease of 19.54+/-15.81% in the control group (P=0.002). The present study indicates the existence of functional ECE activity in rat basilar artery, which differs in the endothelium and the smooth muscle layer. These results demonstrate that [D-Val22]big ET-1 [16-38] has a potent ECE-inhibitory effect, preventing cerebral vasospasm in rabbit basilar artery by inhibiting the transformation of big ET-1 to vasoactive ET-1 after intracisternal application in vivo, whereas no inhibitory effect was detectable in rat basilar artery in vitro. Therefore, further studies of the biochemical nature of cerebrovascular ECE activity are required.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12962299     DOI: 10.1007/s10143-002-0242-9

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  57 in total

1.  In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors.

Authors:  V Breu; B M Löffler; M Clozel
Journal:  FEBS Lett       Date:  1993-11-15       Impact factor: 4.124

2.  D-Val22 containing human big endothelin-1 analog, [D-Val22]Big ET-1[16-38], inhibits the endothelin converting enzyme.

Authors:  A Morita; M Nomizu; M Okitsu; K Horie; H Yokogoshi; P P Roller
Journal:  FEBS Lett       Date:  1994-10-10       Impact factor: 4.124

Review 3.  Endothelin receptor antagonists: actions and rationale for their development.

Authors:  T D Warner; B Battistini; A M Doherty; R Corder
Journal:  Biochem Pharmacol       Date:  1994-08-17       Impact factor: 5.858

Review 4.  Inhibition of the pharmacological effects of endothelin.

Authors:  C Wilson; R B Hargreaves
Journal:  Prog Med Chem       Date:  1994

5.  Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47-0203, a newly developed orally active endothelin receptor antagonist.

Authors:  M Zimmermann; V Seifert; B M Löffler; D Stolke; W Stenzel
Journal:  Neurosurgery       Date:  1996-01       Impact factor: 4.654

6.  Contractile response of human omental arteries to endothelin.

Authors:  J M Vila; E Martín de Aguilera; A Irurzun; M Aldasoro; B Flor; S Lluch
Journal:  J Pharm Pharmacol       Date:  1992-02       Impact factor: 3.765

7.  Effect of endothelinA-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm.

Authors:  F Cosentino; E G McMahon; J S Carter; Z S Katusić
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105

8.  Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.

Authors:  P J Kukkola; P Savage; Y Sakane; J C Berry; N A Bilci; R D Ghai; A Y Jeng
Journal:  J Cardiovasc Pharmacol       Date:  1995       Impact factor: 3.105

9.  A novel endothelin ETA receptor antagonist, BQ-485, and its preventive effect on experimental cerebral vasospasm in dogs.

Authors:  S Itoh; T Sasaki; K Ide; K Ishikawa; M Nishikibe; M Yano
Journal:  Biochem Biophys Res Commun       Date:  1993-09-15       Impact factor: 3.575

10.  A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels.

Authors:  M Yanagisawa; H Kurihara; S Kimura; K Goto; T Masaki
Journal:  J Hypertens Suppl       Date:  1988-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.